BIOGBs Stock Overview
A healthcare company, provides probiotic products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
BioGaia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 95.85 |
| 52 Week High | SEK 112.40 |
| 52 Week Low | SEK 92.08 |
| Beta | 0.63 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 10.24% |
| 33 Year Change | -4.34% |
| 5 Year Change | 39.72% |
| Change since IPO | 117.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOGBs | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | 2.2% |
| 1Y | 10.2% | -18.3% | 8.0% |
Return vs Industry: BIOGBs exceeded the UK Biotechs industry which returned -28.7% over the past year.
Return vs Market: BIOGBs exceeded the UK Market which returned -2.4% over the past year.
Price Volatility
| BIOGBs volatility | |
|---|---|
| BIOGBs Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BIOGBs has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BIOGBs's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 213 | Theresa Agnew | www.biogaia.com |
BioGaia AB (publ), a healthcare company, develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula.
BioGaia AB (publ) Fundamentals Summary
| BIOGBs fundamental statistics | |
|---|---|
| Market cap | SEK 10.15b |
| Earnings (TTM) | SEK 437.42m |
| Revenue (TTM) | SEK 1.27b |
23.2x
P/E Ratio8.0x
P/S RatioIs BIOGBs overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOGBs income statement (TTM) | |
|---|---|
| Revenue | SEK 1.27b |
| Cost of Revenue | SEK 340.23m |
| Gross Profit | SEK 932.79m |
| Other Expenses | SEK 495.37m |
| Earnings | SEK 437.42m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 07, 2024
| Earnings per share (EPS) | 4.33 |
| Gross Margin | 73.27% |
| Net Profit Margin | 34.36% |
| Debt/Equity Ratio | 0% |
How did BIOGBs perform over the long term?
See historical performance and comparison